JP2020518669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518669A5 JP2020518669A5 JP2020511737A JP2020511737A JP2020518669A5 JP 2020518669 A5 JP2020518669 A5 JP 2020518669A5 JP 2020511737 A JP2020511737 A JP 2020511737A JP 2020511737 A JP2020511737 A JP 2020511737A JP 2020518669 A5 JP2020518669 A5 JP 2020518669A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 230000004655 Hippo pathway Effects 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000003733 ovarian melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 0 CC(C)Nc1c(*)cccc1 Chemical compound CC(C)Nc1c(*)cccc1 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500937P | 2017-05-03 | 2017-05-03 | |
| US62/500,937 | 2017-05-03 | ||
| PCT/US2018/030721 WO2018204532A1 (en) | 2017-05-03 | 2018-05-02 | Non-fused tricyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518669A JP2020518669A (ja) | 2020-06-25 |
| JP2020518669A5 true JP2020518669A5 (enExample) | 2021-07-26 |
Family
ID=64016799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511737A Pending JP2020518669A (ja) | 2017-05-03 | 2018-05-02 | 非縮合三環式化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11186554B2 (enExample) |
| EP (1) | EP3618818A4 (enExample) |
| JP (1) | JP2020518669A (enExample) |
| CN (1) | CN111132673A (enExample) |
| AU (1) | AU2018263921A1 (enExample) |
| CA (1) | CA3062294A1 (enExample) |
| WO (1) | WO2018204532A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111132673A (zh) | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
| CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| EP3720430A4 (en) | 2017-12-06 | 2021-05-05 | Vivace Therapeutics, Inc. | BENZOCARBONYL COMPOUNDS |
| CA3100503A1 (en) | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
| CN109260200A (zh) * | 2018-11-21 | 2019-01-25 | 南方科技大学 | 化合物dCTB在制备治疗癌性疼痛的药物中的应用 |
| GB201819659D0 (en) | 2018-12-03 | 2019-01-16 | Vib Vzw | Cancer regression by inducing a regeneration-like reponse |
| MX2021011209A (es) * | 2019-03-15 | 2022-01-19 | Massachusetts Gen Hospital | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. |
| EP3956033B1 (en) * | 2019-04-16 | 2024-12-11 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| MX2021014443A (es) * | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| AU2020282759A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CN114174291A (zh) * | 2019-07-29 | 2022-03-11 | 巴斯利尔药物国际股份公司 | 用于治疗癌症的1,2,4-噁二唑-5-酮衍生物 |
| EP4146652A1 (en) * | 2020-05-08 | 2023-03-15 | Merck Patent GmbH | Tricyclic heterocycles useful as tead binders |
| WO2021247634A1 (en) * | 2020-06-03 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| PE20240017A1 (es) | 2020-09-30 | 2024-01-04 | Univ Leuven Kath | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| JP2024505196A (ja) | 2021-01-25 | 2024-02-05 | イケナ オンコロジー， インコーポレイテッド | 肺癌の処置において使用するためのｔｅａｄ阻害剤３－（イミダゾール－４－イル）－４－（アミノ）－ベンゼンスルホンアミドとｅｇｆｒ阻害剤及び／またはｍｅｋ阻害剤との組み合わせ |
| WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN115594680A (zh) * | 2021-07-07 | 2023-01-13 | 武汉人福创新药物研发中心有限公司（Cn） | 一种tead抑制剂 |
| CN113461643A (zh) * | 2021-07-20 | 2021-10-01 | 韶远科技（上海)有限公司 | 一种4-甲基苯磺酸[(3-氟氧杂环丁烷-3-基)甲基]酯的合成方法 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4441056A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| IL312905A (en) | 2021-12-01 | 2024-07-01 | Boehringer Ingelheim Int | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099612A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US20250145608A1 (en) | 2021-12-01 | 2025-05-08 | Boehringer Ingelheim Int'l GmbH Corp. | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| US20250313553A1 (en) | 2021-12-01 | 2025-10-09 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099623A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US12030866B2 (en) | 2021-12-23 | 2024-07-09 | Springworks Therapeutics, Inc. | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD |
| WO2023116877A1 (zh) * | 2021-12-24 | 2023-06-29 | 武汉人福创新药物研发中心有限公司 | 作为tead抑制剂的杂环化合物 |
| JP2025503671A (ja) * | 2022-01-14 | 2025-02-04 | デウン ファーマシューティカル カンパニー リミテッド | 癌細胞成長抑制効果を有する新規アミノベンゼン誘導体およびこれを有効成分として含む予防または治療用薬剤学的組成物 |
| TW202340180A (zh) * | 2022-01-30 | 2023-10-16 | 大陸商希格生科（深圳）有限公司 | 三環化合物及其應用 |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023204822A1 (en) * | 2022-04-22 | 2023-10-26 | Vivace Therapeutics, Inc. | Phenyl phosphine oxide compounds and methods of use thereof |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| AU2023262556A1 (en) | 2022-04-28 | 2024-12-05 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| EP4592302A1 (en) * | 2022-09-23 | 2025-07-30 | Hangzhou Phecdamed Co., Ltd. | Small molecule compound having phosphorylated aryl structure, and use thereof |
| UY40457A (es) | 2022-09-29 | 2024-04-02 | Insilico Medicine Ip Ltd | Inhibidores de tead y métodos de uso de los mismos |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| WO2024105610A1 (en) | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| CN120659608A (zh) | 2023-02-23 | 2025-09-16 | 诺华股份有限公司 | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 |
| US20250019385A1 (en) | 2023-05-30 | 2025-01-16 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2025088571A1 (en) | 2023-10-26 | 2025-05-01 | Astrazeneca Ab | Crystalline forms of tead inhibitor |
| WO2025141118A1 (en) | 2023-12-27 | 2025-07-03 | Institut National de la Santé et de la Recherche Médicale | Arylalkyloxyindole compounds and derivatives and their use |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903106A (en) | 1974-04-12 | 1975-09-02 | Lilly Co Eli | Pyrazole-3-carboxylic acids |
| US3895027A (en) | 1974-04-12 | 1975-07-15 | Lilly Co Eli | Process for preparing pyrazole-3-carboxylic acids |
| DE2419970C3 (de) | 1974-04-25 | 1980-06-12 | Hoechst Ag, 6000 Frankfurt | 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung |
| JP2630432B2 (ja) | 1987-08-24 | 1997-07-16 | コニカ株式会社 | 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料 |
| FI902771A7 (fi) | 1989-06-09 | 1990-12-10 | Warner Lambert Co | Menetelmä anti-inflammatoristen 1,3,4-tiadiatsolien ja 1,3,4-oksadiatsolien valmistamiseksi |
| US4962119A (en) | 1989-06-09 | 1990-10-09 | Warner-Lambert Company | Triazole derivatives of fenamates as antiinflammatory agents |
| US5066668A (en) | 1989-06-09 | 1991-11-19 | Warner-Lambert Co. | Triazole derivatives of fenamates as antiinflammatory agents |
| US5114958A (en) | 1991-05-09 | 1992-05-19 | Warner-Lambert Company | 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents |
| US5670526A (en) | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6211209B1 (en) | 1997-08-08 | 2001-04-03 | Warner-Lambert Company | Method of inhibiting connective tissue degradation |
| DE69926914T2 (de) | 1999-01-13 | 2006-06-29 | Warner-Lambert Co. Llc | 1-heterozyklus-substituierte diarylaminen |
| US6972287B1 (en) | 1999-06-10 | 2005-12-06 | Pfizer Inc. | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| CA2377100A1 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| AU2003293376A1 (en) * | 2002-12-10 | 2004-06-30 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| US20090048301A1 (en) | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| CA2582247C (en) | 2004-10-20 | 2014-02-11 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
| US8097650B2 (en) | 2005-07-27 | 2012-01-17 | The Trustees Of Columbia University In The City Of New York | Method of treating a condition associated with phosphorylation of TASK-1 |
| ZA200807263B (en) | 2006-04-19 | 2009-11-25 | Serono Lab | Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors |
| WO2008057280A1 (en) * | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| US8785440B2 (en) | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| KR101880966B1 (ko) * | 2011-06-10 | 2018-07-23 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| EP2858635A1 (en) | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| CN106573918B (zh) | 2014-07-04 | 2020-06-16 | 默克专利股份有限公司 | 具有抗寄生虫活性的氮杂环庚烷基衍生物和包含它们的药物组合物 |
| JP2018519245A (ja) | 2015-04-03 | 2018-07-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| DK3371165T3 (da) * | 2015-11-04 | 2022-05-02 | Merck Patent Gmbh | Btk-inhibitor til anvendelse til behandling af kræft |
| CN111132673A (zh) | 2017-05-03 | 2020-05-08 | 维瓦斯治疗公司 | 非稠合三环化合物 |
| CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| EP3720430A4 (en) | 2017-12-06 | 2021-05-05 | Vivace Therapeutics, Inc. | BENZOCARBONYL COMPOUNDS |
| CA3100503A1 (en) | 2018-05-16 | 2019-11-21 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
-
2018
- 2018-05-02 CN CN201880045048.0A patent/CN111132673A/zh active Pending
- 2018-05-02 WO PCT/US2018/030721 patent/WO2018204532A1/en not_active Ceased
- 2018-05-02 CA CA3062294A patent/CA3062294A1/en not_active Abandoned
- 2018-05-02 US US16/609,715 patent/US11186554B2/en active Active
- 2018-05-02 EP EP18794672.8A patent/EP3618818A4/en not_active Withdrawn
- 2018-05-02 AU AU2018263921A patent/AU2018263921A1/en not_active Abandoned
- 2018-05-02 JP JP2020511737A patent/JP2020518669A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518669A5 (enExample) | ||
| JP2020533280A5 (enExample) | ||
| JP2019535744A5 (enExample) | ||
| JP2016520131A5 (enExample) | ||
| CY1121142T1 (el) | Τυποποιηση ενωσεων βορονικου οξεος | |
| JP2020533277A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2012505916A5 (enExample) | ||
| IL311645B1 (en) | 2,5-Dimethomers of 3-methylpyrazines and 2,5,6-Trimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors | |
| JP2017095457A5 (enExample) | ||
| RU2014135401A (ru) | Производные пиридона | |
| JP2010511721A5 (enExample) | ||
| JPWO2020097389A5 (enExample) | ||
| JP2013522292A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2015531371A5 (enExample) | ||
| RU2005132408A (ru) | Ингибиторы киназы | |
| JP2009511490A5 (enExample) | ||
| JP2019511565A5 (enExample) | ||
| ES2300775T3 (es) | Furazanobencimidazoles. | |
| JP2016506958A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2017530171A5 (enExample) | ||
| JP2008504304A5 (enExample) |